A novel protocol for de-isolating moderately and severely immunocompromised COVID-19 patients-Reference-Cited by-同舟云学术

A novel protocol for de-isolating moderately and severely immunocompromised COVID-19 patients

Published:2023-12-31 Issue:6 Volume:5 Page:366-371
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Kamegai Kohei¹,Iwamoto Noriko¹,Ishikane Masahiro¹,Yamamoto Kei¹,Horii Kumi²,Kubota Shiho²,Hangaishi Akira³,Shimazu Hiroshi³,Togano Tomiteru³,Yamashita Hiroyuki⁴,Yamada Yasuhide⁵,Ohmagari Norio¹

Affiliation:

1. Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

2. Infection Control Office, National Center for Global Health and Medicine, Tokyo, Japan.

3. Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.

4. Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan.

5. Comprehensive Cancer Center, National Center for Global Health and Medicine, Tokyo, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/ghm/5/6/5_2023.01053/_pdf

Reference27 articles.

1. 1. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html (accessed August 27, 2023).

2. 2. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised (accessed April 8, 2023).

3. 3. Sepulcri C, Dentone C, Mikulska M, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-A case study. Open Forum Infect Dis. 2021; 8:ofab217.

4. 4. IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decisionmaking. Updated March 12, 2021. https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf (accessed April 8, 2023).

5. 5. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021; 27:1990-2001.